{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:36:47Z","timestamp":1787319407965,"version":"build-2736575974"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"crossref","award":["NRF2022R1F1A1064221"],"award-info":[{"award-number":["NRF2022R1F1A1064221"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"crossref","award":["NRF2018R1A5A2024425"],"award-info":[{"award-number":["NRF2018R1A5A2024425"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"crossref","award":["MEST"],"award-info":[{"award-number":["MEST"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"crossref","award":["RS-2023-00218616"],"award-info":[{"award-number":["RS-2023-00218616"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100002551","name":"Seoul National University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002551","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Mol Med"],"published-print":{"date-parts":[[2026,12]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>\n                      Non-alcoholic fatty liver disease and atherosclerosis may share a common pathogenesis involving chronic IL-1\u03b2-induced inflammation. We aimed to evaluate the efficacy of diacerein, an IL-1 pathway inhibitor, in improving liver fibrosis, steatosis, and atherosclerosis in apolipoprotein E-knockout (apoE k\/o) mice. ApoE k\/o mice fed a high-fat diet (HFD) were divided into three groups based on diacerein dosage. Liver fat accumulation and fibrosis severity were compared across groups, along with changes in the expression of genes related to lipid metabolism and fibrosis. Atherosclerotic burden in the aorta was evaluated via\n                      <jats:italic>en face<\/jats:italic>\n                      analysis, and the related signaling pathway was verified in vitro. Diacerein treatment reduced the amount of collagen fibers and fat accumulation in the liver in a dose-dependent manner as well as fibrosis-related gene expression. Atherosclerotic plaque burden in the aorta showed a decreasing trend with diacerein treatment, accompanied by reduced expression of pro-inflammatory cytokines, including TNF-\u03b1. Diacerein treatment ameliorated liver steatosis\/fibrosis and showed beneficial effects on atherosclerosis-related mechanisms in HFD-fed apoE k\/o mice. Given its dual anti-inflammatory and anti-fibrotic actions, diacerein represents a promising therapeutic candidate for metabolic disorders characterized by chronic inflammation.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Key messages<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>We analyzed the effects of diacerein on liver fibrosis, steatosis, and atherosclerosis in apolipoprotein E knockout (apoE k\/o) mice.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Diacerein reduced fat accumulation in the liver and collagen fibers in the liver.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>It decreased the expression of genes related to fibrosis and the burden of atherosclerotic plaque in the aorta.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>The expression of pro-inflammatory cytokines was reduced.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Treatment of apoE knockout mice fed an HFD with diacerein effectively ameliorated liver steatosis\/fibrosis and atherosclerosis.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical Abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1007\/s00109-026-02653-1","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T07:53:19Z","timestamp":1773215599000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Diacerein improves liver fibrosis, steatosis, and atherosclerosis in ApoE knockout mice"],"prefix":"10.1007","volume":"104","author":[{"given":"Jie-Eun","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isom","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung-Jae","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jisu","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jee-In","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo-Rahm","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae Jung","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun Kyung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0740-8116","authenticated-orcid":false,"given":"Sung Hee","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,11]]},"reference":[{"issue":"9","key":"2653_CR1","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","volume":"7","author":"K Riazi","year":"2022","unstructured":"Riazi K, Azhari H, Charette JH, Underwood FE, King JA, Afshar EE et al (2022) The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 7(9):851\u2013861","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"2653_CR2","doi-asserted-by":"publisher","first-page":"841","DOI":"10.3350\/cmh.2022.0239","volume":"28","author":"MH Le","year":"2022","unstructured":"Le MH, Yeo YH, Zou B, Barnet S, Henry L, Cheung R et al (2022) Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach. Clin Mol Hepatol 28(4):841\u2013850","journal-title":"Clin Mol Hepatol"},{"key":"2653_CR3","unstructured":"Mortality GBD (2016) Causes of Death C. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980\u20132015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 388(10053):1459\u2013544."},{"issue":"3","key":"2653_CR4","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/S2468-1253(16)30081-4","volume":"1","author":"P Gines","year":"2016","unstructured":"Gines P, Graupera I, Lammert F, Angeli P, Caballeria L, Krag A et al (2016) Screening for liver fibrosis in the general population: a call for action. Lancet Gastroenterol Hepatol 1(3):256\u2013260","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"2653_CR5","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1111\/j.1467-9450.2009.00722.x","volume":"51","author":"JP Vernat","year":"2010","unstructured":"Vernat JP, Gordon MS (2010) Indirect interception actions by blind and visually impaired perceivers: echolocation for interceptive actions. Scand J Psychol 51(1):75\u201383","journal-title":"Scand J Psychol"},{"issue":"9","key":"2653_CR6","doi-asserted-by":"publisher","first-page":"e107265","DOI":"10.1371\/journal.pone.0107265","volume":"9","author":"KA Negrin","year":"2014","unstructured":"Negrin KA, Roth Flach RJ, DiStefano MT, Matevossian A, Friedline RH, Jung D et al (2014) IL-1 signaling in obesity-induced hepatic lipogenesis and steatosis. PLoS ONE 9(9):e107265","journal-title":"PLoS ONE"},{"issue":"6","key":"2653_CR7","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1016\/j.immuni.2013.11.010","volume":"39","author":"C Garlanda","year":"2013","unstructured":"Garlanda C, Dinarello CA, Mantovani A (2013) The interleukin-1 family: back to the future. Immunity 39(6):1003\u20131018","journal-title":"Immunity"},{"issue":"1","key":"2653_CR8","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1159\/000282083","volume":"28","author":"H Tilg","year":"2010","unstructured":"Tilg H (2010) The role of cytokines in non-alcoholic fatty liver disease. Dig Dis 28(1):179\u2013185","journal-title":"Dig Dis"},{"issue":"8","key":"2653_CR9","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1016\/j.jacc.2018.11.050","volume":"73","author":"EP Stahl","year":"2019","unstructured":"Stahl EP, Dhindsa DS, Lee SK, Sandesara PB, Chalasani NP, Sperling LS (2019) Nonalcoholic fatty liver disease and the heart: JACC state-of-the-art review. J Am Coll Cardiol 73(8):948\u2013963","journal-title":"J Am Coll Cardiol"},{"issue":"20","key":"2653_CR10","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1161\/CIRCULATIONAHA.117.030484","volume":"136","author":"GK Hansson","year":"2017","unstructured":"Hansson GK (2017) Inflammation and atherosclerosis: the end of a controversy. Circulation 136(20):1875\u20131877","journal-title":"Circulation"},{"issue":"9","key":"2653_CR11","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1161\/ATVBAHA.108.179705","volume":"32","author":"P Libby","year":"2012","unstructured":"Libby P (2012) Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol 32(9):2045\u20132051","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"2","key":"2653_CR12","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1056\/NEJM199901143400207","volume":"340","author":"R Ross","year":"1999","unstructured":"Ross R (1999) Atherosclerosis\u2013an inflammatory disease. N Engl J Med 340(2):115\u2013126","journal-title":"N Engl J Med"},{"key":"2653_CR13","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3389\/fcvm.2019.00016","volume":"6","author":"AW Aday","year":"2019","unstructured":"Aday AW, Ridker PM (2019) Targeting residual inflammatory risk: a shifting paradigm for atherosclerotic disease. Front Cardiovasc Med 6:16","journal-title":"Front Cardiovasc Med"},{"issue":"12","key":"2653_CR14","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","volume":"377","author":"PM Ridker","year":"2017","unstructured":"Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C et al (2017) Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 377(12):1119\u20131131","journal-title":"N Engl J Med"},{"key":"2653_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23094906","author":"EJ Ku","year":"2022","unstructured":"Ku EJ, Kim BR, Lee JI, Lee YK, Oh TJ, Jang HC et al (2022) The anti-atherosclerosis effect of anakinra, a recombinant human interleukin-1 receptor antagonist, in apolipoprotein E knockout mice. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms23094906","journal-title":"Int J Mol Sci"},{"issue":"20","key":"2653_CR16","doi-asserted-by":"publisher","first-page":"2662","DOI":"10.1161\/CIRCULATIONAHA.107.731877","volume":"117","author":"I Ikonomidis","year":"2008","unstructured":"Ikonomidis I, Lekakis JP, Nikolaou M, Paraskevaidis I, Andreadou I, Kaplanoglou T et al (2008) Inhibition of interleukin-1 by anakinra improves vascular and left ventricular function in patients with rheumatoid arthritis. Circulation 117(20):2662\u20132669","journal-title":"Circulation"},{"issue":"3","key":"2653_CR17","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.amjcard.2014.11.003","volume":"115","author":"A Abbate","year":"2015","unstructured":"Abbate A, Kontos MC, Abouzaki NA, Melchior RD, Thomas C, Van Tassell BW et al (2015) Comparative safety of interleukin-1 blockade with anakinra in patients with ST-segment elevation acute myocardial infarction (from the VCU-ART and VCU-ART2 pilot studies). Am J Cardiol 115(3):288\u2013292","journal-title":"Am J Cardiol"},{"issue":"5","key":"2653_CR18","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.jhep.2024.01.031","volume":"80","author":"S Gawrieh","year":"2024","unstructured":"Gawrieh S, Dasarathy S, Tu W, Kamath PS, Chalasani NP, McClain CJ et al (2024) Randomized trial of anakinra plus zinc vs. prednisone for severe alcohol-associated hepatitis. J Hepatol 80(5):684\u2013693","journal-title":"J Hepatol"},{"issue":"1","key":"2653_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-017-0623-6","volume":"16","author":"Y Tian","year":"2017","unstructured":"Tian Y, Chen T, Wu Y, Yang L, Wang L, Fan X et al (2017) Pioglitazone stabilizes atherosclerotic plaque by regulating the Th17\/Treg balance in AMPK-dependent mechanisms. Cardiovasc Diabetol 16(1):140","journal-title":"Cardiovasc Diabetol"},{"issue":"2","key":"2653_CR20","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/S0005-8165(73)80016-2","volume":"150","author":"H Puchtler","year":"1973","unstructured":"Puchtler H, Waldrop FS, Valentine LS (1973) Polarization microscopic studies of connective tissue stained with picro-sirius red FBA. Beitr Pathol 150(2):174\u2013187","journal-title":"Beitr Pathol"},{"issue":"7","key":"2653_CR21","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.2337\/dc11-0357","volume":"34","author":"MG Ramos-Zavala","year":"2011","unstructured":"Ramos-Zavala MG, Gonzalez-Ortiz M, Martinez-Abundis E, Robles-Cervantes JA, Gonzalez-Lopez R, Santiago-Hernandez NJ (2011) Effect of diacerein on insulin secretion and metabolic control in drug-naive patients with type 2 diabetes: a randomized clinical trial. Diabetes Care 34(7):1591\u20131594","journal-title":"Diabetes Care"},{"issue":"10","key":"2653_CR22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0186554","volume":"12","author":"F Piovesan","year":"2017","unstructured":"Piovesan F, Tres GS, Moreira LB, Andrades ME, Lisboa HK, Fuchs SC (2017) Effect of diacerein on renal function and inflammatory cytokines in participants with type 2 diabetes mellitus and chronic kidney disease: a randomized controlled trial. PLoS One 12(10):e0186554","journal-title":"PLoS One"},{"issue":"5","key":"2653_CR23","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1111\/dom.13643","volume":"21","author":"NC Leite","year":"2019","unstructured":"Leite NC, Viegas BB, Villela-Nogueira CA, Carlos FO, Cardoso CRL, Salles GF (2019) Efficacy of diacerein in reducing liver steatosis and fibrosis in patients with type 2 diabetes and non-alcoholic fatty liver disease: a randomized, placebo-controlled trial. Diabetes Obes Metab 21(5):1266\u20131270","journal-title":"Diabetes Obes Metab"},{"issue":"7","key":"2653_CR24","doi-asserted-by":"publisher","first-page":"5863","DOI":"10.1007\/s11033-022-07366-5","volume":"49","author":"GA Mohamed Kamel","year":"2022","unstructured":"Mohamed Kamel GA, Harahsheh E, Hussein S (2022) Diacerein ameliorates acetaminophen hepatotoxicity in rats via inhibiting HMGB1\/TLR4\/NF-kappaB and upregulating PPAR-gamma signal. Mol Biol Rep 49(7):5863\u20135874","journal-title":"Mol Biol Rep"},{"issue":"5","key":"2653_CR25","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1007\/s11010-022-04369-5","volume":"477","author":"H Kang","year":"2022","unstructured":"Kang H, Seo E, Oh YS, Jun HS (2022) TGF-beta activates NLRP3 inflammasome by an autocrine production of TGF-beta in LX-2 human hepatic stellate cells. Mol Cell Biochem 477(5):1329\u20131338","journal-title":"Mol Cell Biochem"},{"key":"2653_CR26","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/7269150","volume":"2020","author":"Y Tao","year":"2020","unstructured":"Tao Y, Wang N, Qiu T, Sun X (2020) The role of autophagy and NLRP3 inflammasome in liver fibrosis. Biomed Res Int 2020:7269150","journal-title":"Biomed Res Int"},{"issue":"1","key":"2653_CR27","first-page":"1","volume":"37","author":"L Campana","year":"2017","unstructured":"Campana L, Iredale JP (2017) Regression of liver fibrosis. Semin Liver Dis 37(1):1\u201310","journal-title":"Semin Liver Dis"},{"issue":"6","key":"2653_CR28","doi-asserted-by":"publisher","first-page":"G1324","DOI":"10.1152\/ajpgi.90564.2008","volume":"296","author":"RG Gieling","year":"2009","unstructured":"Gieling RG, Wallace K, Han YP (2009) Interleukin-1 participates in the progression from liver injury to fibrosis. Am J Physiol Gastrointest Liver Physiol 296(6):G1324\u2013G1331","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"2653_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232415791","author":"CM Flessa","year":"2022","unstructured":"Flessa CM, Nasiri-Ansari N, Kyrou I, Leca BM, Lianou M, Chatzigeorgiou A et al (2022) Genetic and diet-induced animal models for non-alcoholic fatty liver disease (NAFLD) research. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms232415791","journal-title":"Int J Mol Sci"},{"key":"2653_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.951093","volume":"13","author":"X Li","year":"2022","unstructured":"Li X, Zhong S, Sun Y, Huang X, Li Y, Wang L et al (2022) Integration analysis identifies the role of metallothionein in the progression from hepatic steatosis to steatohepatitis. Front Endocrinol (Lausanne) 13:951093","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2653_CR31","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2022.12841","author":"K Matsumoto","year":"2022","unstructured":"Matsumoto K, Kato Y, Hayashi M, Miura R, Monzen S, Chiba M (2022) Hepatic gene expression and functional changes associated with nonalcoholic steatohepatitis. Mol Med Rep. https:\/\/doi.org\/10.3892\/mmr.2022.12841","journal-title":"Mol Med Rep"},{"issue":"11","key":"2653_CR32","doi-asserted-by":"publisher","first-page":"4080","DOI":"10.1210\/en.2011-0249","volume":"152","author":"N Tobar","year":"2011","unstructured":"Tobar N, Oliveira AG, Guadagnini D, Bagarolli RA, Rocha GZ, Araujo TG et al (2011) Diacerhein improves glucose tolerance and insulin sensitivity in mice on a high-fat diet. Endocrinology 152(11):4080\u20134093","journal-title":"Endocrinology"},{"issue":"5","key":"2653_CR33","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1002\/hep.24001","volume":"52","author":"H Tilg","year":"2010","unstructured":"Tilg H, Moschen AR (2010) Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 52(5):1836\u20131846","journal-title":"Hepatology"},{"issue":"8","key":"2653_CR34","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1016\/j.metabol.2015.12.012","volume":"65","author":"E Buzzetti","year":"2016","unstructured":"Buzzetti E, Pinzani M, Tsochatzis EA (2016) The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism 65(8):1038\u20131048","journal-title":"Metabolism"},{"issue":"3","key":"2653_CR35","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.112.002006","volume":"1","author":"A Denes","year":"2012","unstructured":"Denes A, Drake C, Stordy J, Chamberlain J, McColl BW, Gram H et al (2012) Interleukin-1 mediates neuroinflammatory changes associated with diet-induced atherosclerosis. J Am Heart Assoc 1(3):e002006","journal-title":"J Am Heart Assoc"},{"issue":"3","key":"2653_CR36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0173981","volume":"12","author":"GC Mohan","year":"2017","unstructured":"Mohan GC, Zhang H, Bao L, Many B, Chan LS (2017) Diacerein inhibits the pro-atherogenic & pro-inflammatory effects of IL-1 on human keratinocytes & endothelial cells. PLoS One 12(3):e0173981","journal-title":"PLoS One"},{"issue":"1","key":"2653_CR37","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1002\/hep4.1789","volume":"6","author":"S Subudhi","year":"2022","unstructured":"Subudhi S, Drescher HK, Dichtel LE, Bartsch LM, Chung RT, Hutter MM et al (2022) Distinct hepatic gene-expression patterns of NAFLD in patients with obesity. Hepatol Commun 6(1):77\u201389","journal-title":"Hepatol Commun"},{"issue":"2","key":"2653_CR38","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/S0168-8278(96)80027-4","volume":"24","author":"T Ueno","year":"1996","unstructured":"Ueno T, Tamaki S, Sugawara H, Inuzuka S, Torimura T, Sata M et al (1996) Significance of serum tissue inhibitor of metalloproteinases-1 in various liver diseases. J Hepatol 24(2):177\u2013184","journal-title":"J Hepatol"},{"issue":"2","key":"2653_CR39","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1055\/a-0713-1330","volume":"51","author":"SA Polyzos","year":"2019","unstructured":"Polyzos SA, Slavakis A, Koumerkeridis G, Katsinelos P, Kountouras J (2019) Noninvasive liver fibrosis tests in patients with nonalcoholic fatty liver disease: an external validation cohort. Horm Metab Res 51(2):134\u2013140","journal-title":"Horm Metab Res"},{"key":"2653_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.110594","volume":"131","author":"M Almezgagi","year":"2020","unstructured":"Almezgagi M, Zhang Y, Hezam K, Shamsan E, Gamah M, Al-Shaebi F et al (2020) Diacerein: recent insight into pharmacological activities and molecular pathways. Biomed Pharmacother 131:110594","journal-title":"Biomed Pharmacother"},{"issue":"2","key":"2653_CR41","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s40266-016-0347-4","volume":"33","author":"K Pavelka","year":"2016","unstructured":"Pavelka K, Bruyere O, Cooper C, Kanis JA, Leeb BF, Maheu E et al (2016) Diacerein: benefits, risks and place in the management of osteoarthritis. An opinion-based report from the ESCEO. Drugs Aging 33(2):75\u201385","journal-title":"Drugs Aging"},{"issue":"3","key":"2653_CR42","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1053\/joca.1999.0289","volume":"8","author":"F Moldovan","year":"2000","unstructured":"Moldovan F, Pelletier JP, Jolicoeur FC, Cloutier JM, Martel-Pelletier J (2000) Diacerhein and rhein reduce the ICE-induced IL-1beta and IL-18 activation in human osteoarthritic cartilage. Osteoarthritis Cartilage 8(3):186\u2013196","journal-title":"Osteoarthritis Cartilage"},{"issue":"4","key":"2653_CR43","first-page":"753","volume":"25","author":"J Martel-Pelletier","year":"1998","unstructured":"Martel-Pelletier J, Mineau F, Jolicoeur FC, Cloutier JM, Pelletier JP (1998) In vitro effects of diacerhein and rhein on interleukin 1 and tumor necrosis factor-alpha systems in human osteoarthritic synovium and chondrocytes. J Rheumatol 25(4):753\u2013762","journal-title":"J Rheumatol"},{"issue":"3","key":"2653_CR44","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1053\/joca.1998.0201","volume":"7","author":"M Yaron","year":"1999","unstructured":"Yaron M, Shirazi I, Yaron I (1999) Anti-interleukin-1 effects of diacerein and rhein in human osteoarthritic synovial tissue and cartilage cultures. Osteoarthritis Cartilage 7(3):272\u2013280","journal-title":"Osteoarthritis Cartilage"},{"issue":"15","key":"2653_CR45","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1056\/NEJM199704103361506","volume":"336","author":"PJ Barnes","year":"1997","unstructured":"Barnes PJ, Karin M (1997) Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 336(15):1066\u20131071","journal-title":"N Engl J Med"},{"issue":"10","key":"2653_CR46","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.2337\/dc17-0374","volume":"40","author":"CRL Cardoso","year":"2017","unstructured":"Cardoso CRL, Leite NC, Carlos FO, Loureiro AA, Viegas BB, Salles GF (2017) Efficacy and safety of diacerein in patients with inadequately controlled type 2 diabetes: a randomized controlled trial. Diabetes Care 40(10):1356\u20131363","journal-title":"Diabetes Care"},{"issue":"2","key":"2653_CR47","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1590\/2359-3997000000242","volume":"61","author":"MM Villar","year":"2017","unstructured":"Villar MM, Martinez-Abundis E, Preciado-Marquez RO, Gonzalez-Ortiz M (2017) Effect of diacerein as an add-on to metformin in patients with type 2 diabetes mellitus and inadequate glycemic control. Arch Endocrinol Metab 61(2):188\u2013192","journal-title":"Arch Endocrinol Metab"},{"key":"2653_CR48","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/4246521","volume":"2018","author":"GS Tres","year":"2018","unstructured":"Tres GS, Fuchs SC, Piovesan F, Koehler-Santos P, Pereira FDS, Camey S et al (2018) Effect of diacerein on metabolic control and inflammatory markers in patients with type 2 diabetes using antidiabetic agents: a randomized controlled trial. J Diabetes Res 2018:4246521","journal-title":"J Diabetes Res"},{"issue":"1","key":"2653_CR49","doi-asserted-by":"publisher","DOI":"10.1186\/s13104-022-05974-9","volume":"15","author":"J Jangsiripornpakorn","year":"2022","unstructured":"Jangsiripornpakorn J, Srisuk S, Chailurkit L, Nimitphong H, Saetung S, Ongphiphadhanakul B (2022) The glucose-lowering effect of low-dose diacerein and its responsiveness metabolic markers in uncontrolled diabetes. BMC Res Notes 15(1):91","journal-title":"BMC Res Notes"}],"updated-by":[{"DOI":"10.1007\/s00109-026-02674-w","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:00:00Z","timestamp":1776124800000}}],"container-title":["Journal of Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00109-026-02653-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00109-026-02653-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00109-026-02653-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T01:01:55Z","timestamp":1776128515000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00109-026-02653-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,11]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["2653"],"URL":"https:\/\/doi.org\/10.1007\/s00109-026-02653-1","relation":{},"ISSN":["0946-2716","1432-1440"],"issn-type":[{"value":"0946-2716","type":"print"},{"value":"1432-1440","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,11]]},"assertion":[{"value":"15 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2026","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00109-026-02674-w","URL":"https:\/\/doi.org\/10.1007\/s00109-026-02674-w","order":9,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The experimental procedures were compiled with the Guide for Experimental Animal Research of the Laboratory for Experimental Animal Research, Clinical Research Institute, Seoul National University Bundang Hospital, Republic of Korea.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"50"}}